IRAK1 and acute lymphoblastic leukemia: In order to determine whether IRAK inhibitors could enhance the cytotoxic effects of chemotherapeutic agents, we screened nearly 500 FDA-approved drugs for their ability to kill T-ALL cells when combined with IRAK inhibitors.